Ion Beam Applications, SA Stock

Equities

IBAB

BE0003766806

Advanced Medical Equipment & Technology

Market Closed - Euronext Bruxelles 11:35:18 2024-04-26 EDT 5-day change 1st Jan Change
12.86 EUR -0.77% Intraday chart for Ion Beam Applications, SA -3.02% +11.44%

Financials

Sales 2023 429M 458M 627M Sales 2024 * 489M 523M 715M Capitalization 375M 401M 548M
Net income 2023 -9M -9.62M -13.16M Net income 2024 * 4M 4.28M 5.85M EV / Sales 2023 0.63 x
Net cash position 2023 68.46M 73.2M 100M Net cash position 2024 * 62.79M 67.14M 91.79M EV / Sales 2024 * 0.64 x
P/E ratio 2023 *
-25.7 x
P/E ratio 2024 *
91.9 x
Employees 2,000
Yield 2023 *
1.63%
Yield 2024 *
2.1%
Free-Float 65.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.77%
1 week-3.02%
Current month-1.83%
1 month+7.17%
3 months+22.71%
6 months+44.98%
Current year+11.44%
More quotes
1 week
12.80
Extreme 12.8
13.46
1 month
12.78
Extreme 12.78
14.00
Current year
9.31
Extreme 9.31
14.00
1 year
8.26
Extreme 8.26
17.20
3 years
8.26
Extreme 8.26
20.45
5 years
6.01
Extreme 6.01
20.45
10 years
6.01
Extreme 6.01
56.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
Founder 76 86-03-27
Director of Finance/CFO 46 03-12-31
Members of the board TitleAgeSince
Chairman 63 86-12-31
Director/Board Member 77 17-04-30
Founder 76 86-03-27
More insiders
Date Price Change Volume
24-04-26 12.86 -0.77% 19,328
24-04-25 12.96 -2.56% 17,204
24-04-24 13.3 0.00% 7,679
24-04-23 13.3 +0.91% 17,590
24-04-22 13.18 -0.60% 14,637

Real-time Euronext Bruxelles, April 26, 2024 at 11:35 am

More quotes
Ion Beam Applications, SA (IBA) specializes in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. Net sales break down by family of products as follows: - diagnosis and therapeutic treatment equipment and systems (84.8%): proton therapy equipment (62.5% of net sales; No. 1 worldwide), and particle accelerators (36.5%) used in the production of radioisotopes (cyclotrons) and in the development of sterilization and ionization solutions (Rhodotron® and Dynamitron®); - equipment and solutions of dosimetry (15.2%; No. 1 worldwide): measurement and analysis tools of the radiation doses in medical imaging and radiation therapy. Net sales are distributed geographically as follows: the United States (31.7%) and other (68.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.86 EUR
Average target price
16.17 EUR
Spread / Average Target
+25.71%
Consensus

Quarterly revenue - Rate of surprise